These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 21633601)
1. XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls. Yuan L; Cui D; Zhao EJ; Jia CZ; Wang LD; Lu WQ World J Gastroenterol; 2011 May; 17(18):2343-8. PubMed ID: 21633601 [TBL] [Abstract][Full Text] [Related]
2. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies. Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049 [TBL] [Abstract][Full Text] [Related]
3. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies. Ding DP; Ma WL; He XF; Zhang Y Mol Biol Rep; 2012 Mar; 39(3):2533-40. PubMed ID: 21667112 [TBL] [Abstract][Full Text] [Related]
4. XPD Lys751Gln polymorphisms and the risk of esophageal cancer: an updated meta-analysis. Guo XF; Wang J; Lei XF; Zeng YP; Dong WG Intern Med; 2015; 54(3):251-9. PubMed ID: 25748732 [TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis. Ma Q; Qi C; Tie C; Guo Z Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729 [TBL] [Abstract][Full Text] [Related]
6. The effect of XPD polymorphisms on digestive tract cancers risk: a meta-analysis. Du H; Guo N; Shi B; Zhang Q; Chen Z; Lu K; Shu Y; Chen T; Zhu L PLoS One; 2014; 9(5):e96301. PubMed ID: 24787743 [TBL] [Abstract][Full Text] [Related]
7. Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects. Lin H; Lin D; Zheng C Diagn Pathol; 2014 Jan; 9():15. PubMed ID: 24443924 [TBL] [Abstract][Full Text] [Related]
8. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis. Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192 [TBL] [Abstract][Full Text] [Related]
9. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies. Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498 [TBL] [Abstract][Full Text] [Related]
10. Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis. Peng Q; Li S; Lao X; Chen Z; Li R; Qin X Medicine (Baltimore); 2014 Dec; 93(29):e330. PubMed ID: 25546681 [TBL] [Abstract][Full Text] [Related]
11. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis. Yuan H; Niu YM; Wang RX; Li HZ; Chen N Genet Mol Res; 2011 Nov; 10(4):3356-64. PubMed ID: 22179996 [TBL] [Abstract][Full Text] [Related]
12. Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Duan XL; Gong H; Zeng XT; Ni XB; Yan Y; Chen W; Liu GL Asian Pac J Cancer Prev; 2012; 13(7):3299-303. PubMed ID: 22994751 [TBL] [Abstract][Full Text] [Related]
13. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies. Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729 [TBL] [Abstract][Full Text] [Related]
14. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Liu G; Zhou W; Yeap BY; Su L; Wain JC; Poneros JM; Nishioka NS; Lynch TJ; Christiani DC Carcinogenesis; 2007 Jun; 28(6):1254-8. PubMed ID: 17264068 [TBL] [Abstract][Full Text] [Related]
15. Association between the XPD/ERCC2 Lys751Gln polymorphism and risk of cancer: evidence from 224 case-control studies. Wu KG; He XF; Li YH; Xie WB; Huang X Tumour Biol; 2014 Nov; 35(11):11243-59. PubMed ID: 25113251 [TBL] [Abstract][Full Text] [Related]
16. XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis. Cui J; Li D; Shen L; Zhang W; Xu X Tumour Biol; 2014 Jul; 35(7):6335-41. PubMed ID: 24652592 [TBL] [Abstract][Full Text] [Related]
17. XRCC1 and XPD genetic polymorphisms and susceptibility to age-related cataract: a meta-analysis. Chi XX; Liu YY; Shi SN; Cong Z; Liang YQ; Zhang HJ Mol Vis; 2015; 21():335-46. PubMed ID: 25873778 [TBL] [Abstract][Full Text] [Related]
18. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis. Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488 [TBL] [Abstract][Full Text] [Related]
19. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies. Zhan P; Wang Q; Wei SZ; Wang J; Qian Q; Yu LK; Song Y J Thorac Oncol; 2010 Sep; 5(9):1337-45. PubMed ID: 20651612 [TBL] [Abstract][Full Text] [Related]
20. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. Xue H; Lu Y; Lin B; Chen J; Tang F; Huang G PLoS One; 2012; 7(9):e43431. PubMed ID: 23028453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]